Psyence Biomedical Ltd. (PBM)
Nasdaq: PBM · Pharmaceutical Preparations · Toronto · filing with the SEC since 2023
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in March.The Form 20-F filed Jun 22, 2026 for the period ended Mar 31, 2026 is not in EDGAR's company facts yet; its figures here are that filing's own, read from the SEC's financial statement data sets.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period ending | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Report filed | Jun 22, 2026 | Jun 25, 2025 | Jul 29, 2024 | · | · |
| Research and development | 1,466,653 | 342,168 | 954,593 | 1,608,895 | · |
| Sales and marketing | 218,485 | 483,530 | 80,603 | 7,029 | · |
| General and administrative | 892,264 | 1,209,847 | 557,904 | 366,435 | · |
| Finance costs | 9,522 | 9,270 | 52,941 | · | · |
| Interest income | 263,370 | 95,787 | 2,134 | 1,554 | · |
| Share of profit of equity-method investments | -45,239 | · | · | · | · |
| Income before income taxes | -6,232,245 | -3,658,754 | -2,751,584 | -3,234,869 | · |
| Net income | -6,936,421 | 1,011,790 | -51,159,048 | -3,206,403 | · |
| Earnings per share, basic | -12.56 | 32.76r | -29,214.06r | -2,462.875rb | · |
| Earnings per share, diluted | -12.56 | 32.76r | -29,214.06r | -2,462.875rb | · |
| Weighted average shares, basic | 552,282 | 30,887r | 1,744r | 1,338rb | · |
| Weighted average shares, diluted | 552,282 | 30,887r | 1,744r | 1,338rb | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the change of share basis.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
ifrs-full:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
ifrs-full:SalesAndMarketingExpenseGeneral and administrative the cost of running the company itself
ifrs-full:GeneralAndAdministrativeExpenseFinance costs what its borrowing cost
ifrs-full:InterestExpense
ifrs-full:FinanceCostsInterest income what its cash and investments earned
ifrs-full:RevenueFromInterest
ifrs-full:FinanceIncomeShare of profit of equity-method investments its share of companies it partly owns
ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodIncome before income taxes profit before tax
ifrs-full:ProfitLossBeforeTaxNet income the whole group's profit, minority holders' share included
ifrs-full:ProfitLossEarnings per share, basic net income per share outstanding
ifrs-full:BasicEarningsLossPerShareEarnings per share, diluted net income per share, counting every share that could be issued
ifrs-full:DilutedEarningsLossPerShareWeighted average shares, basic the average count of shares outstanding
ifrs-full:WeightedAverageSharesWeighted average shares, diluted the average count with every share that could be issued
ifrs-full:AdjustedWeightedAverageShares